Reference
O'Day K, et al. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. ClinicoEconomics and Outcomes Research : 16 Sep 2013. Available from: URL: http://dx.doi.org/10.2147/CEOR.S47990
Rights and permissions
About this article
Cite this article
Lurasidone trumps other atypical antipsychotics. PharmacoEcon Outcomes News 687, 9 (2013). https://doi.org/10.1007/s40274-013-0730-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0730-x